DOCSLIB.ORG

Creating Stakeholder Value Creating Stakeholder Value

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

8446 Annual Report 2011_Annual Report 2011 15/03/2012 16:27 Page FC1 Shire plc Annual ReportShire 2011 Shire plc Annual Report 2011 Creating stakeholder value Creating stakeholder value Effective treatments and services Commitment to superior treatments Improved public for their patients health and societal value Better lives for patients Superior clinical Brave culture driving evidence and clear innovation to deliver economic benefits value to all Return to enable further investment shire.com 8446 Annual Report 2011_Annual Report 2011 15/03/2012 16:27 Page IFC1 Shire plc Annual Repo Shire trademarks The following are trademarks either owned or licensed by Shire plc or companies within the Shire Group (the “Group” or the “Company”) which are the subject of trademark registrations in certain territories, or which are owned by third parties as indicated and referred to in this Annual Report: ADDERALL XR® (mixed salts of a single entity amphetamine) AGRYLIN® (anagrelide hydrochloride) APLIGRAF® (trademark of Organogenesis, Inc. (“Organogenesis”)) APRISO® (trademark of Salix Pharmaceuticals, Ltd. (“Salix”)) ASACOL® (trademark of Medeva Pharma Suisse AG (used under license by Warner Chilcott Company, LLC (“Warner Chilcott”))) ATRIPLA® (trademark of Bristol Myers Squibb Company (“BMS”) and Gilead Sciences, Inc. (“Gilead”)) BERINERT P® (trademark of Aventis Behring GmbH) ® CALCICHEW range (calcium carbonate with or without vitamin D3) CARBATROL® (carbamazepine extended release capsules) CEREZYME® (trademark of Genzyme Corporation (“Genzyme”)) CINRYZE® (trademark of Viropharma Biologics, Inc.) CLAVERSAL® (trademark of Merckle Recordati) COLAZAL® (trademark of Salix Pharmaceuticals, Inc.) COMBIVIR® (trademark of GlaxoSmithKline (“GSK”)) CONCERTA® (trademark of Alza Corporation (“Alza”)) DAYTRANA® (trademark of Noven Pharmaceutical Inc. (“Noven”)) DERMAGRAFT® (Human Fibroblast-Derived Dermal Substitute) DIPENTUM® (trademark of UCB Pharma Ltd (“UCB”)) DYNEPO® (trademark of Sanofi-Aventis) ELAPRASE® (idursulfase) EPIVIR® (trademark of GSK) EPIVIR-HBV® (trademark of GSK) EPZICOM®/KIVEXA (EPZICOM) (trademark of GSK) EQUASYM® (methylphenidate hydrochloride) EQUASYM XL® (methylphenidate hydrochloride) FIRAZYR® (icatibant) FOSRENOL® (lanthanum carbonate) FABRAZYME® (trademark of Genzyme) HEPTOVIR® (trademark of GSK) INTUNIV® (guanfacine extended release) JUVISTA® (trademark of Renovo Limited (“Renovo”)) KALBITOR® (trademark of Dyax Corporation) KAPVAY® (trademark of Shionogi Pharma, Inc. (“Shionogi”)) LIALDA® (trademark of Giuliani International Limited (“Guiliani”)) MEDIKINET® (trademark of Medice Arzneimittel Pütter GmbH & Co. KG (“Medice”)) METAZYM™ (arylsulfatase-A) METADATE CD® (trademark of UCB Pharma, S.A.) MEZAVANT® (trademark of Guiliani) MICROTROL® (trademark of Supernus Pharmaceuticals, Inc. (“Supernus”)) MOVICOL® (trademark of Edra AG, S.A.) PENTASA® (trademark of Ferring B.V. Corp (“Ferring”)) REMINYL® (galantamine hydrobromide) (United Kingdom (“UK”) and Republic of Ireland) (trademark of J&J, excluding UK and Republic of Ireland) REMINYL XL™ (galantamine hydrobromide) (UK and Republic of Ireland) (trademark of J&J, excluding UK and Republic of Ireland) REPLAGAL® (agalsidase alfa) RESOLOR® (prucalopride) ® RITALIN LA (trademark of Novartis) Content online ® RUCONEST (trademark of Pharming Intellectual Property B.V.) Discover more about our business online at www.shire.com. SALOFALK® (trademark of Dr. Falk Pharma) ® Scanning a QR code with your camera phone will directly SEASONIQUE (trademark of Barr Laboratories, Inc. (“Barr”)) link you to mobile content. QR code reader applications STRATTERA® (trademark of Eli Lilly) are available from your app store. TRIZIVIR® (trademark of GSK) TRUVADA® (trademark of Gilead) VENVANSE (lisdexamfetamine dimesylate) VPRIV® (velaglucerase alfa) VYVANSE® (lisdexamfetamine dimesylate) XAGRID® (anagrelide hydrochloride) ZAVESCA® (trademark of Actelion Pharmaceuticals, Ltd.) ZEFFIX® (trademark of GSK) 3TC® (trademark of GSK) More online at www.shire.com ›› 8446 Annual Report 2011_Annual Report 2011 15/03/2012 16:11 Page 1 Shire plc Annual Report 2011 1 R e Contents v iew o Shire continues to grow. Our proven business Review of our business f 2 Financial highlights o model helps us to deliver on our mission 4 Shire today ur 6 Chairman’s review bus 8 Chief Executive of enabling people with life-altering conditions i Officer’s review n 12 Financial review e to lead better lives, through leading the way ss in our chosen specialist areas. We have a balanced portfolio of differentiated products that have many years of growth still ahead, as well as the potential to expand into Go v further geographies and markets. Our pipeline e rn Governance a is strong and well focused, offering potential n 42 Board of Directors ce 44 Directors’ report drivers of future growth for our portfolio. 48 Corporate governance report 55 Directors’ remuneration Patients are at the heart of our business and report 70 Nomination Committee we are increasingly engaging with a broader report 71 Audit, Compliance & range of stakeholders to ensure that we Risk Committee report 73 Statement of Directors’ develop innovative products that payors and responsibilities policymakers around the world will welcome, as they deliver value to the healthcare system. Fi n a n Our 5,000 plus employees in 29 countries cial Financial statements 74 Independent auditors’ report s are united by our distinctive culture that brings tate 75 Consolidated balance sheets 76 Consolidated statements the needs of our patients to the fore; everyone m of income e 77 Consolidated statements n t at Shire aims to be as brave as the people of changes in equity s 79 Consolidated statements we help. Through focusing on our patients’ of comprehensive income 80 Consolidated statements needs, we strive to meet the needs of all of cash flows 82 Notes to the consolidated our stakeholders. financial statements Othe r Other financial information fin a 125 Other financial information n 129 Shire head offices and cial i main operating locations 130 Shareholder information nf 132 Cautionary statements o rm 134 Parent company financial statements of Shire plc atio n 8446 Annual Report 2011_Annual Report 2011 15/03/2012 16:11 Page 2 2 Shire plc Annual Report 2011 Shire plc Annual Repo Financial highlights Another strong year for Shire with revenues exceeding $4 billion for the first time and Non GAAP diluted earnings per ADS up 26% to $5.34. Total revenue Non GAAP EBITDA (Earnings Before Interest Tax Depreciation and Amortization) Net product sales 2011 $4,263M 2011 $1,478M 3% 7% 2010 $3,471M 2010 $1,165M 25% 2009 $3,008M 2009 $982M 2008 $3,022M 2007 $2,436M 65% US 25% Europe 3% Latin America 23% year-on-year growth in 2011 27% year-on-year growth in 2011 7% Other Non GAAP diluted earnings per ADS 2011 cash flow Total revenues by 2011 $5.34 Cash generation(1) $1,391M 2010: $3,471M –$317M Capital expenditure 2010 $4.23 –$195M Tax and interest payments 10% $879M Free cash flow(1) 2009 $3.49 $95M Disposal of long-term investment 26% –$725M Payment to acquire ABH 64% –$186M Other investing and financing +$63M Net cash inflow (1) Cash generation and Free cash flow are Non GAAP measures. 64% Specialty Pharm 26% Human Genetic Strong cash generation has supported continued 10% Royalties and o 26% year-on-year growth in 2011 investment in our business More online at http://ar2011.shire.com ›› 8446 Annual Report 2011_Annual Report 2011 15/03/2012 16:11 Page 3 c Annual Report 2011 Shire plc Annual Report 2011 3 R e v iew o f o ur bus i n e ss preciation and Amortization) Net product sales by geographic region Year-on-year product growth ($’M) $1,478M 2011 VYVANSE $805M up 27% 3% 7% 2010 VYVANSE $634M 165M 2011 ADDERALL XR $533M up 48% 2010 ADDERALL XR $361M 25% 2011 REPLAGAL $475M up 35% 2010 REPLAGAL $351M 65% 2011 ELAPRASE $465M up 15% 2010 ELAPRASE $404M 2011 LIALDA/MEZAVANT $372M up 27% 2010 LIALDA/MEZAVANT $293M 2011 VPRIV $256M up 79% 65% US 2010 VPRIV $143M 25% Europe 2011 INTUNIV $223M up 34% 3% Latin America 7% Other 2010 INTUNIV $166M Total revenues by businesses $1,391M 2010: $3,471M 2011: $4,263M 3% 7% 10% (1) 79M Free cash flow up 23% rm investment 26% 29% 64% 61% g s. 64% Specialty Pharmaceutical 61% Specialty Pharmaceutical 26% Human Genetic Therapies 29% Human Genetic Therapies tinued 10% Royalties and other revenues 3% Regenerative Medicine 7% Royalties and other revenues 8446 Annual Report 2011_Annual Report 2011 15/03/2012 16:11 Page 4 4 Shire plc Annual Report 2011 Shire plc Annual Repo Shire today We focus on chronic symptomatic diseases in specialist areas of unmet needs through three businesses: 1. Specialty Pharmaceuticals 2. Human Genetic Therapies 3. Regenerative Medicine Not all of these products are available in all countries where Specialty Human Genetic Regenerative Shire operates. Pharmaceuticals (SP) Therapies (HGT) Medicine (RM) ADHD Fabry disease Diabetic foot ulcers ADHD Hunter syndrome ADHD Gaucher disease ADHD Hereditary angioedema Ulcerative colitis Ulcerative colitis Ulcerative colitis Chronic constipation Essential thrombocythaemia Renal disease More online at http://ar2011.shire.com ›› 8446 Annual Report 2011_Annual Report 2011 15/03/2012 16:11 Page 5 c Annual Report 2011 Shire plc Annual Report 2011 5 R e v iew o f o ur We continue to build our pipeline bus i n e with potential products that will ss deliver value to patients and the healthcare system. Specialty Pharmaceuticals Preclinical and Phase 1 Phase 2 Phase 3 Registration erative Human Genetic Therapies
Recommended publications
  • South Dakota Board of Pharmacy Wholesale Distributors; Active, in Good Standing As of October 5, 2018 This Document May Be Used As a Primary Source Verification

    South Dakota Board of Pharmacy Wholesale Distributors; Active, in Good Standing As of October 5, 2018 This Document May Be Used As a Primary Source Verification

    South Dakota Board of Pharmacy Wholesale Distributors; Active, in good standing as of October 5, 2018 This document may be used as a Primary Source Verification Full License Firm Name DBA Address 1 Address 2 City State ZIP Code Expiration Issued 600-2353 3M COMPANY dba 3M ESPE DENTAL PRODUCTS 2111 MCGAW AVE IRVINE CA 92614 12/31/2018 11/10/2014 3M COMPANY-CRITICAL & CHRONIC 600-1277 CARE SOLUTIONS DIVISION dba 3M 601 22ND AVE S BROOKINGS SD 57006 12/31/2018 03/19/2007 600-0107 A & B WELDING SUPPLY CO INC 914 E CHICAGO ST RAPID CITY SD 57701 12/31/2018 01/28/1992 600-1251 A.F. HAUSER INC 4401 E US HWY 30 VALPARAISO IN 46383 12/31/2018 01/03/2007 600-2272 A.P.I. SOLUTIONS INC 25309 FRIENDSHIP RD DAPHNE AL 36526 12/31/2018 03/06/2014 ABBVIE PATIENT ASSISTANCE 600-1372 FOUNDATION 1 N WAUKEGAN RD D-ZZ22, BLDG AP34 NORTH CHICAGO IL 60064 12/31/2018 11/20/2007 600-2058 ABBVIE US LLC 1 N WAUKEGAN RD D-GS02 BLDG AP5 NORTH CHICAGO IL 60064 12/31/2018 07/19/2012 600-2299 ABRAXIS BIOSCIENCE LLC 86 MORRIS AVE SUMMIT NJ 07901 12/31/2018 05/22/2014 600-2952 ACACIA PHARMA INC 440 STEVENS AVE, SUITE 200 SOLANA BEACH CA 92075 12/31/2019 09/27/2018 600-2358 ACADIA PHARMACEUTICALS INC 3611 VALLEY CENTRE DR STE 300 SAN DIEGO CA 92130 12/31/2018 11/19/2014 600-2409 ACARIAHEALTH SOLUTIONS INC 6610 W SAM HOUSTON PKWY N#330 HOUSTON TX 77041 12/31/2018 04/06/2015 600-1552 ACCERA INC 3005 CENTER GREEN DR #205 BOULDER CO 80301 12/31/2018 01/08/2009 600-2657 ACCORD BIOPHARMA INC 1009 SLATER RD STE 210-B DURHAM NC 27703 12/31/2018 11/07/2016 600-1472 ACCORD HEALTHCARE
  • Report Title Election Report for Cases Closed Region(S) (Report Defaults

    Report Title Election Report for Cases Closed Region(S) (Report Defaults

    Report Title Election Report for Cases Closed Region(s) Election Held Date Closed Date (Report Defaults) Between (Report Defaults) and (Report Defaults) Between 10/1/2016 and 9/30/2017 12:00:00 AM Case Type Case Name Labor Org 1 Name State City (Report Defaults) (All Choices) (All Choices) (Report Defaults) (Report Defaults) Election Report for Cases Closed NLRB Elections - Summary Time run: 10/16/2017 8:16:17 AM Case Type No. of Elections Percent Won by Union Total Employees Eligible to Vote Total Valid Votes for Total Valid Votes Against Total Elections 1391 65.0% 92,653 43,607 31,642 RC 1193 71.0% 79,750 37,631 26,806 RD 172 32.0% 12,319 5,757 4,573 RM 26 30.0% 584 219 263 NLRB Elections with 1 Labor Organization Time run: 10/16/2017 8:16:17 AM Region Case Number Case Name Case City State Election Number Valid Votes Labor Org 1 Name Stipulated Certification of Certification Case Closed Type Held Date of Votes for / Consent Representative of Results Closed Reason Eligible Against Labor / Directed Date (Win) Date (Loss) Date Voters Org 1 01, 34 01-RC-181492 GREEN LINE GROUP INC. RC DEDHAM 9/30/2016 211 57 93 INTERNATIONAL Directed WON 12/21/2016 Certific. of BROTHERHOOD OF Representative MA ELECTRICAL WORKERS LOCAL 1228, AFL-CIO 01, 34 01-RC-182252 RENZENBERGER, INC. RC WORCHESTER 9/12/2016 26 2 7 UNITED STEEL, PAPER AND Stipulated WON 10/6/2016 Certific. of FORESTRY, RUBBER, Representative MA MANUFACTURING, ENERGY, ALLIED INDUSTRIAL AND SERVICE WORKE 01, 34 01-RC-182433 J's Associates, LLC RC Springfield 9/8/2016 12 2 8 Area Trades Council of New Stipulated WON 10/3/2016 Certific.
  • S P O T L I G H T Pa R T I C I Pa N

    S P O T L I G H T Pa R T I C I Pa N

    SPOTLIGHT PARTICIPANTS 12 Copyright © 2019 Mercer (US) Inc. All rights reserved. ORGANIZATION LISTING 3M (Minnesota Mining & Manufacturing) Atlas Energy Group LLC City of Overland Park, KS Cleveland Indians Baseball Co. A&E Television Networks Auburn University City of Winston-Salem, NC CliftonLarsonAllen, LLP A.O. Smith Corporation Automatic Data Processing California Health Care Foundation CMA CGM (America) LLC American Automobile Association, Inc., The Automobile Club of Southern California Cabot Oil & Gas Corporation CNH Industrial America LLC Accenture LLP AXA XL Cactus Feeders, Inc. CNO Financial Group Accudyne Industries, LLC Badger Meter, Inc. Cadmus Holding Company CNOOC Petroleum U.S.A. Inc. Advance Auto Parts Baltimore Orioles California Endowment, The CNX Resources ADVICS North America, Inc. Bank of the Ozarks, Inc. California ISO Colorado Rockies Baseball Club AECOM Building & Construction Bank of New York Mellon California Wellness Foundation Cobb Electric Membership Corporation AECOM Enterprise Baptist Health - FL Cambia Health Solutions (Regence Group) Coca-Cola Company, Inc., The AECOM Management Services Crestline Hotels & Resorts, LLC Canadian Imperial Bank of Commerce COG Operating, LLC Aera Energy Services Company Barnes & Noble, Inc. Canadian National Cognizant Technology Solutions Corporation Affinity Federal Credit Union BASF Corporation Canadian Pacific Railway CohnReznick LLP AgReserves Inc. Basin Electric Power Co-op Canadian Solar, Inc. Colby College Agri Beef Company Bates College Capital Group Companies, Inc., The Colonial Group, Inc. American International Group, Inc. (AIG) Battelle Memorial Institute Capital One Financial Corporation Columbia Sportswear Company Aimbridge Hospitality Baylor College of Medicine CarMax Auto Superstores, Inc. Columbia University American Institutes for Research BB&T Corporation Carilion Clinic Columbus McKinnon Corporation Air Liquide USA Blue Cross Blue Shield of Kansas Carrix, Inc.
  • VOLUME II Public School Code of 1949 Goods and Services Expenditures Fiscal Year 2017-2018

    VOLUME II Public School Code of 1949 Goods and Services Expenditures Fiscal Year 2017-2018

    Public School Code of 1949 Goods and Services Expenditures Fiscal Year 2017-2018 VOLUME II Temple University Financial Disclosure Report Purchase of Goods and Services Contracts Notes and Definitions The following report provides the required disclosures for reporting the purchase of goods and services contracts. The University’s Banner Finance System does not include data enabling the distinction between the purchases of goods and services. Therefore, a single report is provided that includes both. Expenditures are categorized in the attached report using the following categories: General Supplies & Services: o General supplies, expendable equipment and software. Health Service Programs: o Animal lab, professional billing and other outside professional services. Insurance: o Malpractice, property, general liability, and employees insurances. Interest & Taxes: o Bond interest, real estate tax and debt service costs. Library: o Books, electronic periodicals, subscriptions and film. Professional Fees & Contracts: o Auditing, legal and collection fees and subcontracts. Property, Plant & Equipment: o Capital equipment, buildings and building improvements. Rent: o Equipment, building and office rentals. Repairs & Maintenance: o Equipment repair, maintenance of buildings and grounds. Telecommunications: o Telephone equipment, data communications and cellular services. Travel: o Travel agency fees, foreign and domestic travel expenses. Utilities: o Electric, gas, water, sewer, steam, chilled water and other miscellaneous utilities expenses. Each entry provides the category into which the purchase falls, the vendor name and address and the amount of the purchase. There is no more than one entry per vendor for a single category within a responsibility center. Purchases of goods and services in the Disclosure Report include those which equal or exceed $1,000 for each vendor from all Budgeted Operating Funds including Temple University Physicians.
  • Economic Development Strategy and Implemenation

    Economic Development Strategy and Implemenation

    MEDIA ECONOMIC DEVELOPMENT STRATEGY AND IMPLEMENTATION PLAN October 31, 2017 REPORT SUBMITTED TO: Jeff Smith, Borough Manager Media Borough 301 N. Jackson Street Media, PA 19063 REPORT SUBMITTED BY: Econsult Solutions, Inc. 1435 Walnut Street, 4th Floor Philadelphia, PA 19102 Econsult Solutions, Inc.| 1435 Walnut Street, 4th floor| Philadelphia, PA 19102 | 215-717-2777 | econsultsolutions.com Media, Pennsylvania | Economic Development Strategy and Implementation Plan | i TABLE OF CONTENTS 1.0 Introduction ............................................................................................................................ 1 1.1 Our Charge and Our Approach ................................................................................ 1 1.2 Overview of the Report ............................................................................................... 2 2.0 Economic Vision and Goals ................................................................................................. 4 2.1 Vision Overview ............................................................................................................ 4 2.2 Public Outreach Methodology .................................................................................. 4 2.3 Summary of Public Outreach Findings ...................................................................... 4 2.4 Principles for the Economic Development Vision and Goals ................................ 5 2.5 Vision Statement .........................................................................................................
  • A Day in the Life of PHMC 2005 Annual Report What a Difference a Day Makes!

    A Day in the Life of PHMC 2005 Annual Report What a Difference a Day Makes!

    Philadelphia Health Management Corporation A day in the life of PHMC 2005 annual report What a difference a day makes! As I head home from work each evening, I find comfort in knowing that staff from PHMC and its affiliates have reached out to thousands of people since the day began. We believe it’s important to reach people where they are, so every day, we’re in community centers, schools, churches, and people’s homes—wherever we need to be to serve the region’s most vulnerable. In 2005, we were fortunate to bring some unique programs into our network of services: · The PHMC Care Clinic, formerly known as the St. Joseph’s Care Clinic, brings vital medical care to people living with HIV and AIDS in North Philadelphia. · The Bridge began managing the new Parkside E-3 Power Center in West Philadelphia, part of a Philadelphia Youth Network initiative that focuses on empowerment, education, and employment for out-of-school youth and youth returning from the juvenile justice system. · The Joseph J. Peters Institute (JJPI) started an innovative screening and counseling program for Philadelphia grade school children who act in sexually inappropriate ways. · The National Nursing Centers Consortium (NNCC) started its popular STUDENTS RUN Philly Style Program, which mentors Philadelphia students through running programs. · The Health Promotion Council (HPC) expanded its nutrition education work. In addition to their work in the School District of Philadelphia, HPC started working with the North Penn., Wissahickon and Souderton school districts in Montgomery County to fight obesity through promoting healthy eating and healthy lifestyles.
  • 2010 Annual Report

    2010 Annual Report

    2010 AnnuAl RepoRt Air Products Celebrating the Innovation of the Past and Its Promise for the Future Financial Highlights 6% 8% Merchant Gases United States 21% • 21% • • Tonnage Gases • Europe Consolidated Consolidated 41% Electronics and Asia • 39% • Sales by Performance Materials Sales by Business Segment Destination • Canada/Latin America/ROW • Equipment and Energy 32% 32% Millions of dollars, except per share 2010 2009 Change For the Year Sales $9,026 $8,256 9% Operating income 1,389 846 64% Operating income (A) 1,485 1,185 25% Net income attributable to Air Products 1,029 631 63% Capital expenditures (A) 1,298 1,475 (12)% Return on capital employed(A) 12.4 % 10.6 % Return on average Air Products shareholders’ equity (B) 19.9 % 13.3 % Operating margin 15.4 % 10.3 % Operating margin(A) 16.5% 14.3% Per Share DollarS Diluted earnings 4.74 2.96 60% Diluted earnings(A) 5.02 4.06 24% Dividends 1.92 1.79 7% Book value 25.94 22.68 14% at Year enD Air Products shareholders’ equity $5,547 $4,792 Shares outstanding (in millions) 214 211 Shareholders 8,300 8,600 Employees (C) 18,300 18,900 (A) Amounts are non-GAAP measures. See pages V and VI for reconciliation to GAAP results. (B) Calculated using income and five-quarter average Air Products shareholders’ equity from continuing operations. (C) Includes full- and part-time employees from continuing and discontinued operations. return on air Products Shareholders’ equity Sales earnings per Share Percentage using income and Air Products Billions of dollars Dollars—diluted basis shareholders’ equity from continuing operations 2010 19.9 2010 9.0 2010 4.74 2009 13.3 2009 8.3 2009 2.96 2008 20.1 2008 10.4 2008 4.15 2007 19.5 2007 9.1 2007 4.64 2006 15.1 2006 7.9 2006 3.18 Air Products | 2010 Annual Report Our Businesses Merchant Gases Industrial and medical customers throughout the world depend on our oxygen, nitrogen, argon, helium, hydrogen, and medical and specialty gases for a wide array of applications.
  • For the PLUS

    For the PLUS

    BUCKS UNITEDANNUAL REPORT united wAy Of bucks county& MAGAZINE Multiplier AwARDS pageS 12-15 BUCKS KNOCKS OUT HUNGER pageS 32-35 CAMPAIGN fOR THE GREATER GOOD pageS 46-49 Local Perspectives on Education, Income & Health, 14 Reasons to Explore PLUS Bucks County, A Local Recipe for Every Season, By the Numbers, and more! United Way of Bucks County Comcast congratulates United Way of Bucks County awards recipients, past and present, including: Brian Jeter Dr. Stanton Kelton Service Award Nan Mauro Paul Sauerbry Award tABLe oF contents 20 36 46 what's cooking? Leading the way Achieving corporate try a recipe for each season from some A local couple's legacy of caring for Philanthropic goals of our favorite local farms. Bucks county. the simple way to bring your team together for the greater good. AnnuAl RepoRt Businesses giving BAck 41 INCOME: Early Investing: 3 Letter from CEO Jamie Haddon 27 GE: Where Giving Back Matters Simple Ways to Teach Our Children about Saving & Investing 5 Letter from CFO John Ramirez 28 Comcast: A Long History of Living United 43 HEALTH: Kicking Off Community 6 Board of Directors & Introduction Health Collaboration of New Board Members 29 National Penn Bank: Sharing Time & Treasure in Local Communities 44 Shaping the Futures of Girls in 7 An Agency with Impact Bucks County Through 8 Kelton Award Winner: Brian Jeter 31 Hill Wallack LLP: Regional Mind, Body & Spirit Strength, Local Impact 10 Sauerbry Award Winner: 46 UW Bucks Campaigns Help You Nan Mauro locAl peRspectives Achieve Corporate Philanthropic Goals 60
  • SHIRE PLC (Exact Name of Registrant As Specified in Its Charter)

    SHIRE PLC (Exact Name of Registrant As Specified in Its Charter)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PLC (Exact name of registrant as specified in its charter) Jersey (Channel Islands) 98-0601486 (State or other jurisdiction of incorporation or (I.R.S. Employer Identification No.) organization) 5 Riverwalk, Citywest Business Campus, Dublin +353 1 429 7700 24, Republic of Ireland (Address of principal executive offices and zip code) (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depositary Shares, each representing three NASDAQ Global Select Market Ordinary Shares 5 pence par value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) 1 Indicate by check mark whether the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act Yes [X] No [ ] Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act Yes [ ] No [X] Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
  • 2020 ANNUAL REPORT Statement of Intentions the Leadingage 1

    2020 ANNUAL REPORT Statement of Intentions the Leadingage 1

    W�'�� changing our stripes 2020 ANNUAL REPORT Statement of Intentions The LeadingAge 1. To carry out our mission in ways that are always Quality First Elements ethical and in the expressed spirit of our stated of Quality mission. Dunwoody Village participates in the 2. To create an atmosphere of caring that treats all LeadingAge Quality First program, which residents in a dignified manner respecting helps organizations to achieve excellence individuality, privacy and personal choices. in aging services and earn public trust. By endorsing the Quality First principles, 3. To create health and wellness programs that serve Dunwoody pledges to work in partnership residents along the full continuum of care. with consumers and the government to 4. To support a quality management program that create an environment of high-quality care identifies, develops and implements and service. The ten elements of quality are: ongoing performance improvement projects. • Commitment 5. To cultivate teamwork in providing distinctive • Governance and Accountability high quality services. • Leading-Edge Care and Services 6. To provide a homelike and welcoming environ- • Community Involvement ment that is safe and secure. • Continuous Quality Improvement 7. To support our mission in a cost-efficient and • Human Resources Development effective manner. • Consumer-Friendly Information 8. To provide charitable Personal Care services to a • Consumer Participation limited number of qualified individuals, in keeping • Research Findings and Education with the vision of our founder, William Hood • Public Trust and Consumer Confidence Dunwoody. 9. To promote and develop strong community affilia- tions through residents, employees, and Trustees. 10. To create an atmosphere of growth and opportunity in order to attract and maintain employees who are committed to our Core Values of Teamwork, Respect, Integrity, Compassion, and Quality.
  • Philly Tech Week 2021 Presented by Comcast Will Be Produced by PACT

    Philly Tech Week 2021 Presented by Comcast Will Be Produced by PACT

    Philly Tech Week 2021 Presented by Comcast will be produced by PACT, in partnership with longtime organizer Technical.ly To be held May 7-15, 2021, the 11th annual will feature a unique collaboration between two of Philadelphia’s tech community anchors PHILADELPHIA (FEBRUARY 10, 2021) -- Today local tech economy news site Technical.ly and regional tech council Philadelphia Alliance for Capital and ​ ​ Technologies (PACT) announce their partnership to produce Philly Tech Week 2021 ​ ​ Presented by Comcast. ​ Since 2010, Technical.ly, which is published by digital media company Technically Media, has served as lead organizer for Philly Tech Week, an annual open calendar of events celebrating technology, entrepreneurship and innovation. The week has always featured a wide array of supportive collaborators and partners, including PACT. This will change for the 11th annual which will take place virtually May 7-15, 2021. A virtual town hall on PTW21 will be held on Monday, Feb. 22. Register here. ​ ​ The two organizations are trialing a partnership in which PACT will leverage its strengths and longstanding history as a convener of the regional tech and healthcare innovation community to serve as lead organizer, with Technical.ly taking a secondary role. PACT will lead community organizing efforts, including managing the week’s community calendar — which routinely includes more than 100 events — and centralize the week’s messaging. Technical.ly will produce its annual future of work conference Introduced and the Technical.ly Developers Conference. The Technical.ly newsroom will continue to track the Philadelphia tech economy, which celebrates innovation in Philadelphia annually with Philly Tech Week.
  • Ryan D. Stottmann Partner

    Ryan D. Stottmann Partner

    Ryan D. Stottmann Partner Wilmington, Delaware [email protected] t 302-351-9430 Ryan’s litigation practice focuses on corporate and commercial PRACTICE AREAS litigation in the Delaware Court of Chancery and appeals before Corporate & Commercial the Delaware Supreme Court. Litigation Complex Commercial Litigation He has served as lead counsel and co-counsel to companies, Mergers & Acquisitions stockholders and directors in appraisal and fiduciary duty litigation, Litigation trade secrets and licensing cases, employee non-compete and non- Shareholder Class & Derivative solicitation matters, statutory matters arising under Delaware corporate Litigation and alternative entity laws, and post-closing indemnification and escrow disputes arising from merger, stock purchase or asset purchase EDUCATION agreements. University of Maryland School of Law, JD, cum laude, 2008 Ryan has represented both plaintiffs and defendants from a variety of Maryland Law Review, associate industries, including technology, finance, software and electronics, real editor, 2007-2008; staff member, estate management, healthcare, telecommunications, chemicals, and 2006-2007 pharmaceuticals. York College of Pennsylvania, BA, political science, summa Ryan also advises company boards and special committees on cum laude, 2005 stockholder-related matters, including stockholder litigation demands ADMISSIONS and demands for corporate reforms. Delaware, 2008 He frequently appears before the Delaware Superior Court, including US District Court for the District the Complex Commercial Litigation Division, and the US District Court of Delaware, 2009 for the District of Delaware. Since 2018, Ryan has appeared on Benchmark Litigation’s annual “40 & Under Hot List” recognizing litigation attorneys in the United States. 1201 North Market Street, 16th Floor, PO Box 1347, Wilmington, DE 19899-1347 morrisnichols.com Ryan D.